Trials / Not Yet Recruiting
Not Yet RecruitingNCT07244666
Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 19 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A Study of Metabolically Armed EGFRvII CAR-T Cells Therapy for Patients With Recurrent Glioblastoma
Detailed description
1. Primary Objective Evaluate the safety and efficacy of metabolically armed EGFRvIII CAR-T cell injection in patients with recurrent glioblastoma. 2. Secondary Objectives Evaluate the pharmacokinetics/pharmacodynamic characteristics of metabolically armed EGFRvIII CAR-T cells in patients with recurrent glioblastoma and the persistence of the CAR-T cells in the subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metabolically Armed EGFRvIII CAR-T cells | Patients will receive a single infusion of Meta10-EGFRvIII. |
Timeline
- Start date
- 2025-11-15
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
- First posted
- 2025-11-24
- Last updated
- 2025-11-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07244666. Inclusion in this directory is not an endorsement.